Horizon Kinetics Medical ETF (MEDX) Stock Forecast
Alert
Its only available to paid users.
N/A
Based on the Horizon Kinetics Medical ETF stock forecast from 0 analysts, the average analyst target price for Horizon Kinetics Medical ETF is not available over the next 12 months. Horizon Kinetics Medical ETF’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Horizon Kinetics Medical ETF is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, Horizon Kinetics Medical ETF’s stock price was USD 27.74. Horizon Kinetics Medical ETF’s stock price has changed by +0.89% over the past week, -6.78% over the past month and 0% over the last year.
No recent analyst target price found for Horizon Kinetics Medical ETF
No recent average analyst rating found for Horizon Kinetics Medical ETF
Company Overview Horizon Kinetics Medical ETF
The fund is an actively-managed exchange-traded fund ("ETF") that pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets plus any borrowings for investment purposes in common stocks, convertible securities, warrants and other equity securities having the characteristics of common stocks of U.S. and foreign companies engaged in medical research, pharmaceutical and medical technology industries and related technology industries. The fund is non-diversified. Read Less
The fund is an actively-managed exchange-traded fund ("ETF") that pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets plus any borrowings for investment purposes in common stocks, convertible securities, warrants and other equ...Read More
N/A
N/A
2,245
N/A
USD
USA
N/A
N/A
N/A
0.85 %
Adjusted Closing Price for Horizon Kinetics Medical ETF (MEDX)
Loading...
Unadjusted Closing Price for Horizon Kinetics Medical ETF (MEDX)
Loading...
Share Trading Volume for Horizon Kinetics Medical ETF Shares
Loading...
Compare Performance of Horizon Kinetics Medical ETF Shares
Frequently Asked Questions About Horizon Kinetics Medical ETF (MEDX) Stock
Stock Target Advisor's fundamental analysis for Horizon Kinetics Medical ETF's stock is Bearish.
MEDX stock's dividend yield is 1.30%.
Our analysis grades MEDX stock's dividend yield at F. This means that MEDX stock's dividend yield is above 32% of the stocks in the Others sector in the NSD exchange.
Based on this MEDX may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on MEDX's stock to indicate what its average analyst target is.
MEDX stock's Price/Earning ratio is 80.00.
Our analysis grades MEDX stock's Price / Earning ratio at F. This means that MEDX stock's Price/Earning ratio is above 83% of the stocks in the Others sector in the NSD exchange.
Based on this MEDX may be a overvalued for its sector.
The last closing price of MEDX's stock was USD 27.74.
The most recent market capitalization for MEDX is USD 0.02B.
Unfortunately we do not have enough analyst data on MEDX's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Horizon Kinetics Medical ETF's stock.
As per our most recent records Horizon Kinetics Medical ETF has 2,245 Employees.
Sorry we do not have any infomation available on Horizon Kinetics Medical ETF's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for MEDX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
